The aim of this study was to know the prevalence and severity of COVID-19 in patients treated with long-term macrolides and to describe the factors associated with worse outcomes. A cross-sectional study was conducted in Primary Care setting. Patients with macrolides dispensed continuously from 1 October 2019 to 31 March 2020, were considered. Main outcome: diagnosis of coronavirus disease-19 (COVID-19). Secondary outcomes: symptoms, severity, characteristics of patients, comorbidities, concomitant treatments. A total of 3057 patients met the inclusion criteria. Median age: 73 (64–81) years; 55% were men; 62% smokers/ex-smokers; 56% obese/overweight. Overall, 95% of patients had chronic respiratory diseases and four comorbidities as a median. Prevalence of COVID-19: 4.8%. This was in accordance with official data during the first wave of the pandemic. The most common symptoms were respiratory: shortness of breath, cough, and pneumonia. Additionally, 53% percent of patients had mild/moderate symptoms, 28% required hospital admission, and 19% died with COVID-19. The percentage of patients hospitalized and deaths were 2.6 and 5.8 times higher, respectively, in the COVID-19 group (p < 0.001). There was no evidence of a beneficial effect of long-term courses of macrolides in preventing SARS-CoV-2 infection or the progression to worse outcomes in old patients with underlying chronic respiratory diseases and a high burden of comorbidity.
Background: Exposure to medicines during pregnancy is frequent, even more during first trimester as pregnant women might not be aware of their condition. Aiming to establish potential relationship of earlier exposure to medicines and risk of abortion we conducted an observational study.
Methods: this is a retrospective case-control study of abortions (cases) and live birth pregnancies (controls) matched by mother age using SIDIAP database (Catalan Primary Health electronic health records database). Exposure to medicines while pregnant was considered to assess the risk of abortion during the first trimester. The odds ratio was estimated by a conditional logistic regression and adjust by health conditions and medicines exposures.
Results: A total of 60,350 episodes of abortions were matched to 118,085 live birth/completed pregnancy episodes. Cases had higher rates of alcohol intake (9.9% vs 7.2%), smoking (4.5% vs 3.6%) and of previous abortions (9.9% vs 7.8%). Anxiety (30.3% and 25.1%), respiratory diseases (10.6% and 9.2%) and migraine (8.2% and 7.3%), for cases and controls respectively, were the most frequent baseline conditions. Cases had higher rate of exposure to medicines [40,148 (66.5%) vs 37636 (68.9%), p<0.001, cases and controls respectively]. A risk for abortion was found for antihistamines for systemic use (ORadj 1.23, 95%CI 1.19-1.27), antidepressants (ORadj 1.11, 95%CI 1.06-1.17), anxiolytics (ORadj 1.31, 95%CI 1.26-1.73), and anti-inflammatory and rheumatic products, non-steroids (ORadj 1. 63, 95%CI 1.59-1.67).
Conclusions: These highest rate of medicines exposures during the first trimester of pregnancy and their relationship with abortion highlights the relevance of prescription to women with childbearing potential and may lead to better family planning information and contraception plans.
Registration: EUPAS37675
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.